Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose pulsatile sunitinib versus TAS-102 in metastatic colorectal carcinoma
2017-000364-15Phase 2Terminated
- Sponsor
- VU University Medical Center, Department of Medical
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing High-dose pulsatile sunitinib with TAS-102 monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Sep 2019; status: terminated.
02
Drugs
sunitinibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2017-000364-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000364-15.